These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

536 related articles for article (PubMed ID: 19038465)

  • 1. Reference pricing and firms' pricing strategies.
    Miraldo M
    J Health Econ; 2009 Jan; 28(1):176-97. PubMed ID: 19038465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reference pricing of pharmaceuticals.
    Brekke KR; Königbauer I; Straume OR
    J Health Econ; 2007 May; 26(3):613-42. PubMed ID: 17188769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Competition and the Reference Pricing Scheme for pharmaceuticals.
    Ghislandi S
    J Health Econ; 2011 Dec; 30(6):1137-49. PubMed ID: 21937137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.
    Stargardt T; Schreyögg J
    Appl Health Econ Health Policy; 2006; 5(4):235-47. PubMed ID: 17249840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effects].
    Stargardt T; Schreyögg J; Busse R
    Gesundheitswesen; 2005 Jul; 67(7):468-77. PubMed ID: 16103970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach.
    Augurzky B; Göhlmann S; Gress S; Wasem J
    Health Econ; 2009 Apr; 18(4):421-36. PubMed ID: 18677725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The strategic interaction between firms and formulary committees: effects on the prices of new drugs.
    García-Alonso MD; García-Mariñoso B
    J Health Econ; 2008 Mar; 27(2):377-404. PubMed ID: 18276026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in external price referencing in Europe: a descriptive overview.
    Leopold C; Vogler S; Mantel-Teeuwisse AK; de Joncheere K; Leufkens HG; Laing R
    Health Policy; 2012 Jan; 104(1):50-60. PubMed ID: 22014843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceutical pricing and reimbursement reforms in Greece.
    Yfantopoulos J
    Eur J Health Econ; 2008 Feb; 9(1):87-97. PubMed ID: 17619920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of external price referencing of pharmaceuticals in Middle East countries.
    Kaló Z; Alabbadi I; Al Ahdab OG; Alowayesh M; Elmahdawy M; Al-Saggabi AH; Tanzi VL; Al-Badriyeh D; Alsultan HS; Ali FM; Elsisi GH; Akhras KS; Vokó Z; Kanavos P
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):993-8. PubMed ID: 26088919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value-based differential pricing: efficient prices for drugs in a global context.
    Danzon P; Towse A; Mestre-Ferrandiz J
    Health Econ; 2015 Mar; 24(3):294-301. PubMed ID: 24327269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Price-Directed Search, Product Differentiation and Competition.
    Obradovits M; Plaickner P
    Rev Ind Organ; 2023; 63(3):317-348. PubMed ID: 37786646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retail price regulation and innovation: reference pricing in the pharmaceutical industry.
    Bardey D; Bommier A; Jullien B
    J Health Econ; 2010 Mar; 29(2):303-16. PubMed ID: 20053474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reducing Reimbursement Drug Price Risk to Enhance R&D Incentives without Raising Drug Prices/Expenditures: Implications of Simulations Based on Questionnaire Survey of Pharmaceutical Companies in Japan.
    Nakamura H; Wakutsu N
    Health Policy; 2020 Jul; 124(7):714-720. PubMed ID: 32475740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical pricing dynamics in an internal reference pricing system: evidence from changing drugs' reimbursements.
    Costa E; Santos C
    Eur J Health Econ; 2022 Dec; 23(9):1497-1518. PubMed ID: 35192093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Why drug prices are high in sub-Saharan Africa. Analysis of price structure: the case of Senegal].
    Guimier JM; Candau D; Garenne M; Teulières L
    Sante; 2005; 15(1):41-52. PubMed ID: 15919632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mechanics and effects of European reference pricing for vaccines in Germany according to §130a Abs. 2 SGB V: an analysis using the example of influenza vaccines].
    Barth J; Hammerschmidt T; Vollmar J; Bierbaum M; Schöffski O
    Gesundheitswesen; 2014 Apr; 76(4):e7-e13. PubMed ID: 24081570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pricing of multiple dosage prescription medications: an analysis of the Ontario Drug Benefit Formulary.
    Lexchin J
    Health Policy; 2009 Jul; 91(2):142-7. PubMed ID: 19147251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002.
    Andersson K; Petzold MG; Sonesson C; Lönnroth K; Carlsten A
    Health Policy; 2006 Dec; 79(2-3):231-43. PubMed ID: 16473436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of generic reference pricing interventions in the statin market.
    Puig-Junoy J
    Health Policy; 2007 Nov; 84(1):14-29. PubMed ID: 17368619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.